newsfilter
← Latest News
GlobeNewswire·

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical studies for